NCT05258058: urochester

Feasibility of the Memory and Attention Adaptation-Training Geriatrics Intervention in Older Cancer Survivors With Mild Cognitive Impairment

Completed NA Results posted Last updated 10 July 2024

What this trial tests

NA trial testing Memory and Adaptation Training-Geriatrics in Cognitive Dysfunction in 12 participants. Completed in 26 July 2023.

Timeline

10 December 2021

Primary endpoint
20 July 2023

26 July 2023

Quick facts

Lead sponsor	Allison Magnuson
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	12
Start date	10 December 2021
Primary completion	20 July 2023
Estimated completion	26 July 2023
Sites	1 location across United States

Drugs / interventions tested

• Memory and Adaptation Training-Geriatrics

Conditions studied

• Cognitive Dysfunction — all drugs for Cognitive Dysfunction →

Sponsor

Allison Magnuson

Who can join

65 and older, any sex, with Cognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

MAAT-G Feasibility Completion Rate Primary · 10 Weeks

Evaluate the feasibility of MAAT-G in older cancer survivors with mild cognitive impairment by determining study completion rate of this population.

Group	Value	95% CI
MAAT-G Intervention	10

Proportion of Patients Who Described at Least One MAAT-G Skill Secondary · 10 Weeks

To obtain descriptive feedback on the usability of the intervention and guide further adaptation, qualitative interviews with patients and their caregivers (if available) will be conducted at completion of the intervention.

Group	Value	95% CI
MAAT-G Intervention	9

Change in Cognitive Function (Pre-Post Changes Functional Assessment of Cancer Therapy-Cognition [FACT-Cog]) Secondary · 10 Weeks

Examine the pre-post change in perceived and objective cognitive function in older cancer survivors with MCI using the Functional Assessment of Cancer Therapy-Cognition (FACT-Cog version 2): a 37 item scale assessing perceived cognitive impairment (Total score range 0-185, higher score indicates better cognitive function). Mean change from baseline score is reported.

Group	Value	95% CI
MAAT-G Intervention	6.39	± 12.20

Mean Usability Secondary · 10 Weeks

Enhance our understanding of the usability of a telehealth CRCD intervention (including barriers and facilitators) for older cancer survivors with MCI and the perceived MAAT-G intervention effect using the System Usability Scale (SUS) (a score on a 10-item scale, with a total score ranging from 0-100; a higher score corresponds to greater usability).

Group	Value	95% CI
MAAT-G Intervention	78.75	± 15.332

MAAT-G Intervention Adherence Rate Primary · 10 Weeks

Evaluate the feasibility of MAAT-G in older cancer survivors with mild cognitive impairment by determining the study intervention adherence rate of this population (proportion of MAAT-G workshops completed).

Group	Value	95% CI
MAAT-G Intervention	88.33

Sponsor's own description

Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is a cognitive behavioral therapy-based intervention tailored specifically for older adults and the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment (MCI) is being evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.